Nucleoside-lipid-based nanocarriers for methylene blue delivery: potential application as anti-malarial drug.
Journal
RSC advances
ISSN: 2046-2069
Titre abrégé: RSC Adv
Pays: England
ID NLM: 101581657
Informations de publication
Date de publication:
14 Jun 2019
14 Jun 2019
Historique:
received:
05
04
2019
accepted:
29
05
2019
entrez:
6
5
2022
pubmed:
17
6
2019
medline:
17
6
2019
Statut:
epublish
Résumé
Nucleolipid supramolecular assemblies are promising Drug Delivery Systems (DDS), particularly for nucleic acids. Studies based on negatively and positively charged nucleolipids (diC16dT and DOTAU, respectively) demonstrated appropriate stability, safety, and purity profile to be used as DDS. Methylene Blue (MB) remains a good antimalarial drug candidate, and could be considered for the treatment of uncomplicated or severe malaria. However, the development of MB as an antimalarial drug has been hampered by a high dose regimen required to obtain a proper effect, and a short plasmatic half life. We demonstrated that nanoparticles formed by nucleolipid encapsulation of MB using diC16dT and DOTAU (MB-NPs) is an interesting approach to improve drug stability and delivery. MB-NPs displayed sizes, PDI, zeta values, and colloidal stability allowing a possible use in intravenous formulations. Nanoparticles partially protected MB from oxido-reduction reactions, thus preventing early degradation during storage, and allowing prolongated pharmacokinetic in plasma. MB-NPs' efficacy, tested
Identifiants
pubmed: 35516884
doi: 10.1039/c9ra02576f
pii: c9ra02576f
pmc: PMC9064961
doi:
Types de publication
Journal Article
Langues
eng
Pagination
18844-18852Informations de copyright
This journal is © The Royal Society of Chemistry.
Déclaration de conflit d'intérêts
There are no conflicts to declare.
Références
Comput Methods Programs Biomed. 2011 Oct;104(1):10-8
pubmed: 20828858
Bioconjug Chem. 2009 Sep;20(9):1765-72
pubmed: 19711898
Antimicrob Agents Chemother. 2005 Nov;49(11):4592-7
pubmed: 16251300
Anal Chem. 2019 Feb 5;91(3):1692-1695
pubmed: 30543097
Mem Inst Oswaldo Cruz. 2012 Sep;107(6):820-3
pubmed: 22990975
PLoS One. 2008 Feb 20;3(2):e1630
pubmed: 18286187
J Infect Dis. 2015 Mar 1;211(5):689-97
pubmed: 25267980
Nanoscale Res Lett. 2018 Jan 11;13(1):17
pubmed: 29327307
ACS Nano. 2011 Nov 22;5(11):8649-55
pubmed: 21961944
Int J Antimicrob Agents. 2017 Aug;50(2):155-158
pubmed: 28689867
Antimicrob Agents Chemother. 2012 Jun;56(6):3467-9
pubmed: 22391526
J Antimicrob Chemother. 2002 Aug;50(2):177-87
pubmed: 12161397
Malar J. 2018 Mar 12;17(1):108
pubmed: 29530046
Redox Rep. 2003;8(5):272-5
pubmed: 14962363
Trop Med Int Health. 2010 Jun;15(6):713-7
pubmed: 20374561
Drug Deliv. 2017 Dec;24(sup1):33-44
pubmed: 29069944
Parasitol Res. 2012 Jul;111(1):1-6
pubmed: 22411634
Bioconjug Chem. 2016 Mar 16;27(3):569-75
pubmed: 26751997
Antimicrob Agents Chemother. 2013 Jul;57(7):3412-4
pubmed: 23612202
BMC Med. 2018 Apr 25;16(1):59
pubmed: 29690878
Am J Trop Med Hyg. 2006 Jul;75(1):146-51
pubmed: 16837722
Malar J. 2006 Oct 08;5:84
pubmed: 17026773
Colloids Surf B Biointerfaces. 2010 Nov 1;81(1):263-73
pubmed: 20688493
Antimicrob Agents Chemother. 2011 May;55(5):2472-4
pubmed: 21343466
Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9389-93
pubmed: 9256492
Eur J Clin Pharmacol. 2009 Feb;65(2):179-89
pubmed: 18810398
Bioconjug Chem. 2006 Mar-Apr;17(2):466-72
pubmed: 16536479
J Infect. 2007 Mar;54(3):221-4
pubmed: 16567000
Am J Trop Med Hyg. 2006 Jun;74(6):953-9
pubmed: 16760503
Int J Antimicrob Agents. 2013 Apr;41(4):311-7
pubmed: 23394809
Org Biomol Chem. 2018 Jul 4;16(26):4888-4894
pubmed: 29932190
Exp Parasitol. 2012 Jul;131(3):292-9
pubmed: 22561991
PLoS One. 2009;4(5):e5318
pubmed: 19415120
Antioxid Redox Signal. 2012 Aug 15;17(4):544-54
pubmed: 22256987
Neurobiol Aging. 2011 Dec;32(12):2325.e7-16
pubmed: 21316815
Antimicrob Agents Chemother. 2006 Oct;50(10):3343-9
pubmed: 17005815